New Delhi, December 2019
Under this agreement, Enzene will be granted an exclusive license for manufacturing clinical batches of IDD’s CD 19 product for Phase 1, 2 and 3 clinical trials at its c-GMP compliant manufacturing plant in India. IDD’s anti-CD19 product has the potential to be the “Best-in-class” therapeutic alternative to anti-CD20 MAbs (Monoclonal Antibodies) in failing (refractory, resistant, relapse or association) cases. Enzene’s “Continuous Manufacturing Platform” and fully automated continuous c-GMP compliant manufacturing plant for MAbs production is complementary to IDD’s R&D capabilities.
IDD Biotech, established in 2008, has developed a strong portfolio of MAbs focused on Oncology/ Hematology indications over the last 10 years. During this period, many of IDD’s products have been licensed to global biotech and pharmaceutical companies. Enzene, an innovation driven, fast growing company, based in Pune, India, has developed multiple novel and advanced technological platforms with an aim to disrupt the affordability of biotech products globally.